Company intelligence / Profile preview

Kasvu Therapeutics

Ownership: Private
Employees: ~5
Development stage: Other

Overview

Kasvu Therapeutics is a private Finnish biotechnology company developing non-hallucinogenic neuroplastogens for neuropsychiatric and neurodegenerative disorders. Its lead program, KTX-0141, is an orally designed small-molecule positive allosteric modulator of tropomyosin receptor kinase B (TrkB), intended to enhance endogenous brain-derived neurotrophic factor signaling and neuroplasticity without engaging the serotonin 5-HT2A receptor associated with psychedelic hallucinations. The company is advancing KTX-0141 through IND/CTA-enabling studies for major depressive disorder, with clinical development expected to begin in the second half of 2027. Kasvu was founded in 2023 on research originating at the University of Helsinki and raised a €30 million Series A financing in September 2026 to support Phase 1/1b development.

Therapeutic areas: NeurologyPsychiatry
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

KTX-0141

Preclinical

Beyond the preview

Go deeper on Kasvu Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kasvu Therapeutics.